SEED Therapeutics, a biotechnology company based in King of Prussia, Pennsylvania, has achieved a significant milestone with the FDA’s clearance of its Investigational New Drug (IND) application for ST-01156. This marks the initiation of a groundbreaking Phase 1 clinical trial that targets advanced solid tumor and hematological malignancies by prioritizing cancers with strong preclinical evidence of RBM39 dependency. The first patient dosing for this innovative molecular glue degrader is slated for the first quarter of 2026, setting the stage for potentially transformative outcomes in the treatment landscape.
At the core of SEED’s advancements lies their proprietary RITE3™ platform, a sophisticated system that strategically identifies the most effective E3 ligase for combating disease-related proteins and discovering molecular glues tailored for various disease indications. The debut clinical candidate, ST-01156, has garnered special recognitions including Orphan Drug and Rare Pediatric Disease designations from the FDA, particularly for its application in Ewing sarcoma, a rare pediatric cancer that hasn’t seen new treatment approvals in over three decades. This milestone underscores the power of SEED’s precision-engineered approach to protein degradation, paving the way for a new era of therapeutics with vast potential for enhancing human health.
Dr. Lan Huang, the Co-Founder, Chairman, and CEO of SEED, expressed profound confidence in ST-01156, emphasizing its revolutionary impact on healthcare. This novel medicine promises a paradigm shift in treating RBM39-dependent cancers like Ewing sarcoma, neuroblastoma, and KRAS-driven solid tumors, collectively addressing a patient population exceeding one million globally. Dr. James Tonra, SEED’s President and Chief Scientific Officer, echoed this sentiment, highlighting the strategic fusion of pioneering treatment strategies with expert translational science, which has culminated in the development of ST-01156 supported by robust preclinical data demonstrating tumor regression and precise target engagement.
The mechanism of action of ST-01156 centers on the degradation of RBM39, a pivotal regulator of RNA splicing and transcription that is crucial for the growth and survival of various cancers. Encouraging preclinical results have showcased complete tumor regression in models of Ewing sarcoma, neuroblastoma, and KRAS mutant colon cancer, underscoring the therapeutic potential of this innovative approach. SEED’s commitment to precision medicine is further underscored by the identification of multiple RBM39-dependent cancers through patient-derived models, guiding biomarker-based patient enrollment strategies as ST-01156 progresses into clinical trials under the leadership of Dr. Eric Rowinsky, a distinguished oncology expert with a substantial track record in cancer therapy development.
SEED Therapeutics, founded by luminaries in the field of targeted protein degradation including Nobel Laureate Dr. Avram Hershko, Professor Ning Zheng, Professor Michele Pagano, and Dr. Lan Huang, has attracted significant backing from industry giants like Eli Lilly and Eisai. These collaborations have propelled SEED’s mission to unlock previously inaccessible disease targets, with a diverse pipeline encompassing programs across oncology, neurodegeneration, immunology, and virology. The convergence of cutting-edge science, strategic partnerships, and a relentless pursuit of innovation positions SEED Therapeutics at the forefront of molecular glue degrader discovery, poised to redefine treatment modalities for a spectrum of challenging diseases.
Key Takeaways:
– SEED Therapeutics’ FDA-cleared IND for ST-01156 heralds a new chapter in targeted protein degradation, offering promising avenues for treating RBM39-dependent cancers.
– The innovative RITE3™ platform by SEED showcases a precision-engineered approach to identifying optimal E3 ligases for combating disease-causing proteins and developing molecular glues for diverse disease indications.
– ST-01156’s mechanism of action, centered on degrading RBM39, presents a transformative strategy for addressing various cancers, with compelling preclinical data supporting its efficacy.
– SEED’s strategic partnerships with industry leaders like Eli Lilly and Eisai underscore a collaborative effort to unlock previously untargeted disease proteins and advance therapeutic interventions across multiple disease domains.
Read more on finance.yahoo.com